Skip to main content
. 2018 Sep 5;8(9):e023303. doi: 10.1136/bmjopen-2018-023303

Table 3.

Research nurses: ranking of statements (from most to least important)

Statement Rank Median IQR Range
What are the possible disadvantages and risks of taking part? 1 (most important) 2 2–4 2–4
What is the purpose of this study? 2 2 2.5–4 1–6
What are the possible advantages of taking part? 3 2.5 2–3.5 1–4
What are the possible side effects of trial treatment? 4 2.5 2–4 1–7
What is the treatment that is being tested? 5 3 1.5–4 1–4
What will I have to do? 6 3 2.5–4 2–4
Do I have to take part? 7 3 2.5–4.5 2–6
What will happen to me if I take part? 8 3 3–3.5 1–4
How will my treatment be decided? 9 3 3–4.5 2–5
Why have I been invited? 10 3.5 1–4 1–7
What are the alternatives for treatment? 11 4 3–4 2–5
Will I know what treatment I am on? 12 4 3–5 2–5
What will happen to my treatment when the research study stops? 13 4.5 4–5 3–5
What happens if relevant new information becomes available? 14 5 4–6.5 3–7
What will happen if I don’t want to carry on with the study? 15 5 4.5–5 3–7
Will information from my existing medical records be accessed? 16 5 5–6 5–8
Will there be any impact on any insurance policies? 17 5 5–6 4–7
Will expenses be reimbursed? 18 5 5–6.5 4–7
Will my taking part in the study be kept confidential? 19 5.5 4–6 4–7
Will my general practitioner be told? 20 5.5 4–6.5 3–7
What is involved in the consent process? 21 6 4.5–6 2–7
Who will have access to my data? 22 6 5–6.5 5–7
Will I receive any payments for taking part? 23 6 5–6.5 5–8
Who could I contact for further information? 24 6 5–7 4–7
What will happen to the results of the study? 25 6 5.5–7 5–7
What if I have a complaint? 26 6.5 5.5–7 5–7
Who has overall responsibility for the study? 27 7 5.5–7 5–8
How will data be stored and disposed of? 28 7 5.5–8 5–8
Who is funding the research? 29 8 7.5–9 7–9
Has the scientific quality of study been checked? 30 8 8–8.5 7–9
How have patients and the public been involved in the design of the study? 31 8 8–8.5 6–9
Who has approved the study? 32 (least important) 8 8–9 7–9